• Lab-ready facility jump-starts CDMO operation in Swiss Biotech Cluster

News & Views

Lab-ready facility jump-starts CDMO operation in Swiss Biotech Cluster

Oct 13 2021

Early Autumn saw the launch of ten23 health®, a  globally operating contract development and manufacturing organization (CDMO), supporting biotech start-ups and pharma companies with development of safe injectable biopharmaceutical drugs for patients.

Led by experts with a proven track record in pharmaceutical product design and development, coupled with an extensive global pharma network, the company offers holistic design and development services, building development roadmaps, de-risking strategies and on-going support.

Prof. Dr. Hanns-Christian Mahler, Chief Enabling Officer (CEO) of ten23 health, said: “There is a significant unmet need in the life sciences market. The number and complexity of molecules and novel therapeutic modalities are increasing. Medical research is facing growing challenges with respect to the stability, usability and consistent manufacturing of medicines.

“Our comprehensive offering will allow our clients to focus on the medicine and the patient, whilst leveraging our pharmaceutical expertise and knowledge to plan and de-risk product development to enable commercialisation with speed, quality and success. Our partners will benefit from shorter development timelines, higher probability of technical success and ultimately stronger market positioning as a result.”

The company moved onto the Rosental campus “Rosental Mitte” in Basel, Switzerland, taking over a fully operational lab and office building from Elanco. The building includes around 4’000 square meters of lab and office space providing a work environment for 150 FTEs.

Kaspar Sutter, member of the Government of the Canton of Basel-Stadt and Head of the Department of Economic, Social and Environmental Affairs, commented: “The launch of ten23 health has a positive impact on our dynamic life sciences cluster by creating highly qualified jobs, leveraging local networks and adding to the increasing diversity of pharmaceutical and biotech companies and their strategic partners in our tri-national region.”

More information online

Digital Edition

International Labmate 47.6 - Sept 2022

September 2022

In This Edition Chromatography Articles - Eco-Friendly RP-HPLC Mass Spectrometry & Spectroscopy Articles - Occurrence of PFAS in a variety of fish species from the Baltic Sea and freshw...

View all digital editions


Drug Discovery 2022

Oct 04 2022 London, UK

Dioxin 2022

Oct 09 2022 New Orleans, LA, USA

SPICA 2022

Oct 11 2022 Lisbon, Portugal

WWEM 2022

Oct 12 2022 Telford, UK


Oct 18 2022 Gothenburg, Sweden

View all events